LPP is known to have roles in regulating both metastasis and treatment resistance32-35 and FLRT2 has been identified as tumor suppressive in several cancers.36-38 We also find that established regulators of prostate cancer FOXA1 and SOX5 each contain 3′ UTR mutations across 9 different patient tumors (4.8%).39-42 Interestingly, some of these 3′ UTR mutations are clonal in the patient tumors, while the average mutation is present in ~60% of tumor cells (Figures 1D and S1H). This evidence concerns the gene LPP and prostate carcinoma.